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Abstract A considerable subgroup of patients with early
breast cancer does not address benefits of anthracycline
based chemotherapy. The aim of this retrospective study
was to investigate the effect of microvessel density (MVD)
and status of p53 protein on 5-year disease free survival
(DFS) in the group of breast cancer patients treated with
anthracyclines in adjuvant setting. Correlations between
MVD, p53 status and other clinicopathological parameters
were also assessed. MVD and p53 status were analyzed
immunohistochemically in the group of 172 women with
breast cancer in clinical stage T1-2, N1-N2, M0. There were
123 tumors (71.5 %) with lower MVD (≤214.8 microve-
sells/mm2) and 49 (28.5 %) with higher MVD (>214.8
microvesells/mm2). The proportion of higher MVD tumors
significantly increased in N2 (P00.000) and in estrogen
(P00.046) or progesterone receptors (P00.029) negative
tumors. p53 positivity was indicated in 50 cancers
(29.1 %) and was significantly associated with higher grade
(P00.000), steroid receptors negativity (P00.000), cytoker-
atin5/6 positivity (P00.026), topoisomerase IIα overexpres-
sion (P00.005) and higher proliferation rate (P00.001). In
univariate analysis, higher MVD (P00.016) and p53 nega-
tivity (P00.023) were significantly related with longer DFS
(median follow-up 36 months). In multivariate Cox regres-
sion analysis MVD was independently associated with
DFS. These data suggest that higher MVD is favourable
prognostic factors for early advanced breast cancer patients
after adjuvant anthracycline based chemotherapy.
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Introduction
The clinical outcome of node positive breast cancer is hetero-
geneous despite administration of adjuvant systematic chemo-
therapy with anthracyclines [1, 2]. Therefore, there is a need for
identification of the patients with good prognosis who do not
need further adjuvant treatment and those with worse progno-
sis, for whom alternative, non-anthracycline containing regi-
mens must be applied. The available prognostic parameters
(lymph node status, tumor size, grade of malignancy, expres-
sion of steroid receptors and human epidermal growth factor
receptor type 2 (HER2)) do not define the prognosis of indi-
vidual patient after anthracycline treatment precisely. Hence
extensive research has been carried out to identify novel prog-
nostic factors for a better selection of the optimal treatment. In
the previous retrospective study we have shown that all patients
(n052) with G1+G2 tumors without topoisomerase IIα (TOP-
OIIα) overexpression survived 5 years without progression
after completing anthracyclines treatment [3]. The worst prog-
nosis (DFS: 66.7 %) was found for patients with TOPOIIα
overexpressed and G1+G2 tumors. Thus, there is still a need to
search for new prognostic factors to identify patients with high
risk of metastases development.
Angiogenesis is essential for the growth of both primary and
metastatic tumors. To assess microvessel density, Weidner et al.
[4] suggested identification in tumor specimens of areas with
the highest number of microvessels. They also reported in the
group of 49 patients with primary invasive breast carcinoma,
B. Biesaga (*) : J. Niemiec





Department of Medical Oncology, Centre of Oncology,
ul. Garncarska 11,
Krakow, Poland
Pathol. Oncol. Res. (2012) 18:949–960
DOI 10.1007/s12253-012-9525-9
that higher MVD was associated with axillary lymph nodes or
distant metastases. Since that time, many studies [5, 6] as well
as meta-analysis [7], have shown that lowMVD is related with
good prognosis in breast cancer patients with negative axillary
lymph nodes. However, the role of angiogenesis as a prognostic
factor for adjuvant anthracycline based chemotherapy is un-
clear in women with positive lymph node. In this cohort some
reports [8–10] suggest an association between low MVD and
good prognosis. By contrast, other studies [11–15] failed to
confirm this hypothesis, while in several analyses [16–18]
reverse relation has been found.
Experimental evidence indicates that p53 protein, a product
of tumor suppressor gene, which is a key regulator of cell
response following DNA damage by anthracyclines, addition-
ally influences angiogenesis. p53 contributes to angiogenesis
regulation in two ways: it supports the secretion of inhibitory
thrombospondin-1 and depresses the secretion of the vascular
endothelial growth factor (VEGF) inducer [9]. Although ex-
perimental studies have clearly shown that p53 mutated form
confers resistance to anthracyclines [19, 20], translational
studies have demonstrated non-concordant data. Several
reports [21–24] showed that p53 overexpression assessed by
immunohistochemistry (IHC) correlated with resistance to
anthracyclines, nevertheless other studies suggested lack of
such relation [25–27].
There are two main causes of these discrepancies in the
results of translational researches in the case of both bio-
markers: lack of standardized methods for MVD or p53 status
evaluation and differences between these studies considering
patient selection (N+or/and N−), number of patients enrolled,
use of different polychemotherapy regimens and length of
follow-up. Thus, the prognostic role of MVD and status of
p53 protein in specific subgroups of breast cancer patients
remains controversial. Therefore, in this report we analyzed,
according to our best knowledge for the first time in so large
and homogenous with respect to tumor clinical stage and
adjuvant chemotherapy type, the relation between MVD or
p53 status and DFS in the group of patients with T1-T2, N1-
N2, M0 breast carcinoma, treated with anthracyclines in ad-
juvant setting. Furthermore, we investigated the correlations
between MVD or p53 status and other assessed previously
clinicopathological variables including tumor clinical stage,
grade, estrogen (ER) and progesterone (PgR) receptors,
HER2, cytokeratin 5/6 (CK5/6) status as well as TOPOIIα
expression and proliferation rate.
Material and Methods
Patients
A series of 172 patients with operable (T1-2, N1-2, M0)
invasive primary breast carcinoma treated with adjuvant
anthracyclines based chemotherapy was identified between
2001–2005 at Centre of Oncology, Krakow Branch, Poland.
Details regarding the study population, inclusion and exclusion
criteria, treatment type, immunohistochemical analysis of ste-
roid hormone receptors, CK5/6 and HER2 status, TOPOIIα
expression (by TOPOIIα labelling index (TOPOIIALI)) and
proliferation rate (by Ki-67 labelling index (Ki-67LI)) have
been presented previously [3]. Table 1 summarizes all details
concerning clinical and histopathological characteristics of
patients involved in this study.
The study has been approved by the Ethics Committee at
the Centre of Oncology, Krakow, Poland (date of issue
14.02.2006).
Preparation of Tissue
MVD and p53 status were assessed on formalin fixed and
paraffin-embedded sections. Before staining sections were
deparaffinized in xylenes and rehydrated trough graded
alcohol steps. To quench the endogenous peroxidase activ-
ity, the slides were treated with 0.3 % hydrogen peroxide in
alcohol at 95 % for 30 min. and then washed in distilled
water for 10 min. MVD and p53 status were evaluated IHC.
Immunohistochemistry
In both IHC staining, for antigen unmasking, 50 min incu-
bation in Target Retrieval Solution (TRS), (pH06.1,
DAKOCytomation, Glostrup, Denmark), preheated to 96°
C was applied. The following primary monoclonal antibod-
ies were used: antiCD34 (class II, clone QBEnd 10, Dako-
Cytomation, Glostrup, Denemark, dilution 1:50) and NCL-
p53-1801 (Novocastra, UK, dilution 1:40). In both cases,
whole night incubation with diluted primary antibody at 4°C
in humidity chamber was carried out. The antigen-primary
antibody complex was detected with EnVision+®+System-
HRP (DAB) system (DAKOCytomation, Glostrup, Den-
mark). Peroxidase was visualised using 0.01 % 3.3-diamino-
benzidine tetrahydrochloride (DAB) and 0.015 % hydrogen
peroxide. The slides were counterstained with Mayer’s hema-
toxylin. For negative control, tris buffered saline (TBS) was
substituted for each primary antibody. Positive control in both
stainings includes breast carcinomas exhibiting high expres-
sion of each marker.
Evaluation of IHC Staining
Each section was assessed blind without any knowledge of the
patient’s previous investigations or treatment outcome. MVD
density was determined as previously described by Weidner et
al. [4] using Olympus microscope (Olympus Optic Co., Ltd,
Tokyo, Japan). First, the five areas of invasive component of
tumor with the highest number of microvessels (tumor “hot
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Table 1 Clinical and histological features of breast cancer patients stratifying according to MVD and p53 status
All MVD P-valuea p53LI P-valuea
≤ 214.8 vessel/mm2 > 214.8 vessel/mm2 <0 10 % > 10 %
N (%) N (%) N (%) N (%) N (%)
Number of tumours 172 (100.0) 123 (71.5) 49 (28.5) NS 122 (70.9) 50 (29.1) NS
Age:
<50 years 57 (33.1) 45 (78.9) 12 (21.1) NS 38 (66.7) 19 (33.3) NS
≥50 years 115 (66.9) 78 (67.8) 37 (32.2) 84 (73.0) 31 (27.0)
Tumour size:
T1 53 (30.8) 38 (71.7) 15 (28.3) NS 40 (75.5) 13 (24.5) NS
T2 119 (69.2) 85 (71.4) 34 (28.6) 82 (68.9) 37 (31.1)
Nodal status:
N1 133 (77.3) 108 (81.2) 25 (18.8) 0.000 92 (69.2) 41 (30.8) NS
N2 39 (22.7) 15 (38.5) 24 (61.5) 30 (76.9) 9 (23.1)
Grade:
G1+G2 92 (53.5) 64 (69.6) 28 (30.4) NS 80 (87.0) 12 (13.0) 0.000
G3 80 (46.5) 59 (73.8) 21 (26.2) 42 (52.5) 38 (47.5)
Type of surgery:
Mastectomy 153 (89.0) 112 (73.2) 41 (26.8) NS 110 (71.9) 43 (28.1) NS
BCS 19 (11.0) 11 (57.9) 8 (42.1) 12 (63.2) 7 (36.8)
Type of adjuvant chemotherapy:
AC: 103 (59.9) 62 (60.2) 41 (39.8) 84 (81.5) 19 (18.5)
4 series 51 (49.5) 30 (58.8) 21 (41.2) NS 44 (86.3) 7 (13.7) NS
6 series 52 (50.5) 32 (61.5) 20 (38.5) 40 (76.9) 12 (23.1)
CAF: 69 (40.1) 61 (88.4) 8 (11.6) 38 (55.1) 31 (44.9)
4 series 5 (7.2) 3 (60.0) 2 (40.0) 0.043 3 (60.0) 2 (40.0) NS
6 series 64 (92.8) 58 (90.6) 6 (9.4) 35 (54.7) 29 (45.3)
Estrogen status:
Positive 127 (73.8) 95 (74.8) 32 (25.2) 0.046 104 (81.9) 23 (18.1) 0.000
Negative 45 (26.2) 28 (62.2) 17 (37.8) 18 (40.0) 27 (60.0)
Progesterone status:
Positive 124 (72.1) 92 (74.2) 32 (25.8) 0.029 101 (81.5) 23 (18.5) 0.000
Negative 48 (27.9) 31 (64.6) 17 (35.4) 21 (43.8) 27 (56.3)
Cytokeratin 5/6 expression:
Positive 35 (20.3) 18 (51.4) 17 (48.6) 0.017 18 (51.4) 17 (48.6) 0.026
Negative 137 (79.7) 105 (76.6) 32 (23.4) 104 (75.9) 33 (24.1)
HER2 status:
Overexpressing 68 (39.5) 51 (75.0) 17 (25.0) NS 47 (69.1) 21 (30.9) NS
Not overexpressing 104 (60.6) 72 (69.2) 32 (30.8) 75 (72.1) 29 (27.9)
TOPOIIALIb:
≤11.9 % 84 (48.8) 63 (75.0) 21 (25.0) NS 69 (82.1) 15 (17.9) 0.005
>11.9 % 88 (51.2) 60 (68.2) 28 (31.8) 53 (60.2) 35 (39.8)
Ki-67LIb:
≤19.7 % 98 (57.0) 67 (68.4) 31 (31.6) NS 79 (80.6) 19 (19.4) 0.001
>19.7 % 74 (43.0) 56 (75.7) 18 (24.3) 43 (58.1) 31 (41.9)
MVDc:
≤214.8 vessel/mm2 123 (71.5) 86 (69.9) 37 (30.1) NS
>214.8 vessel/mm2 49 (28.5) 36 (73.5) 13 (26.5)
p53LI:
≤10.0 % 122 (70.9) 86 (70.5) 36 (29.5) NS
>10.0 % 50 (29.1) 37 (74.0) 13 (26.0)
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spot”) were identified at low magnification (X 40). Then, in
each area recognized, the number of individually stained
vessels was counted at X 200 magnification (0.29 mm2 per
field) and MVD was calculated per 1 mm2 (Fig. 1a and b). A
single microvessel was defined as any brown immunostained
endothelial cell that was separated from adjacent microvessel
tumor cell and other connective tissue elements. MVD was
expressed as the mean number of microvessels per mm2, taken
the average from the five “hot-spots” counts.
p53 immunoreactivity was restricted to the nucleus
(Fig. 1c and d). For each section at least 1000 tumors cells
were counted at X 400 magnification. p53 labelling index
(p53LI) was calculated as the percentage of p53 nuclear
immunopositive cells. The sections were graded as positive
if p53LI was >10.0 % of stained tumor cells according to the
value used by other authors [21, 23, 27].
Statistical Analysis
Descriptive statistics was used to determine mean and me-
dian values of continuous variables (MVD, p53LI) and
standard errors of means (SE). Mann-Witney U test was
used to establish the significance of differences between
means of continuous variables. Associations between
Table 1 (continued)
All MVD P-valuea p53LI P-valuea
≤ 214.8 vessel/mm2 > 214.8 vessel/mm2 <0 10% > 10%
N (%) N (%) N (%) N (%) N (%)
Breast cancer immunofenotyped:
Luminal A 80 (46.4) 58 (72.5) 22 (27.5) NS 63 (78.8) 17 (21.2) 0.001
Luminal B 44 (25.6) 34 (77.3) 10 (22.7) 36 (81.8) 8 (18.2)
HER2+ 24 (14.0) 15 (62.5) 9 (37.5) 11 (45.8) 13 (54.2)
Basal-like 24 (14.0) 16 (66.7) 8 (33.3) 12 (50.0) 12 (50.0)
MVDmicrovessel density, p53LI p53 labelling index, BCS breast conserving surgery, AC doxorubicin, cyclophosphamide, CAF cyclophosphamide,
doxorubicin, 5-fluorouracil, TOPOIIALI topoisomerase IIα labelling index, Ki-67LI Ki-67 labelling index, n.s. non significant
a Pearson χ2 (two-sided)
b median value
c 75th percentile
d Luminal A - HER2+ , PgR+ , HER2- , CK5/6- ; Luminal B - ER+ , PgR+ , HER2+ , CK5/6- ; HER2+ - ER- , PgR- , HER2+ CK5/6- ; Basal-like - ER- ,




cells of blood vessels and p53
positive nucleus in breast tumour
tissues. Cancers with higher a
and lower b vascularization
(magnification 100X) or stronger
c and weaker d p53 protein ex-
pression (magnification 200X)
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categorical variables were analyzed using Pearson χ2 test.
The primary endpoint for the study was DFS, defined as the
time from surgery to the first observation of tumor progres-
sion (locoregional recurrence, distant recurrence or second
malignancy). The median duration of DFS was calculated
using the Kaplan-Meier method [28]. Comparisons between
groups were made using log-rank test. Multivariate analysis
was carried out using the Cox proportional hazards model.
Two-sided P values of <0.05 were considered significant. All




Patient characteristic is shown in Table 1 and has also
previously presented in details [3]. Briefly, there were 172
women in age from 32 to 78 years (with mean and median
values 52.8 years±0.67 and 53 years, respectively) with
breast cancer in clinical stage T1N1 (54.7 %), T1N2
(23.3 %), T2N1 (18.0 %) and T2N2 (4.0 %). All women
received anthracyclines as adjuvant chemotherapy accord-
ing to two regimes: doxorubicin/cyclophosphamide (AC) or
cyclophosphamide/5-fluorouracil/doxorubicin (CAF). Of
the initial 172 patients, complete follow-up was available
in 167. The median follow-up time was 36 months (range 3–
64 months). From 167 women, 165 (98.8 %) were alive at
the time of the study, 2 (1.2 %) died from breast cancer after
19 and 14 months from surgery. Tumor progression was
observed in 20 patients (12.1 %).
MVD, p53 Status and Clinical and Histopathological Data
The mean and median values of MVD were 182.9 vessel/
mm2±4.5 (SE) and 173.4 vessel/mm2 (range: 80.8 – 313.3
vessel/mm2), respectively (Fig. 1a and b). Tumors were
classified into lower and higher MVD groups using the
75th percentile (214.8 vessel/mm2) as cutoff point. There
were 123 tumors (71.5 %) with lower MVD and 49 cancers
(28.5 %) with higher MVD. The proportion of tumors with
higher MVD significantly increased in N2 tumors
(P00.000) and in ER (P00.046) or PgR (P00.029) negative
tumors (Table 1). The same was true when MVD was
analyzed as continues variable (data not shown). We did
not observe any other association between MVD and other
clinicopathological variables (Table 1).
The mean and median values of p53LI were 11.5 %±1.9
(SE) and 0.0 % (range: 0.0–90.7 %), respectively (Fig. 1c
and d). p53 status was positive (p53LI>10.0 %) in 50
tumors (29.1 %). p53 positivity was significantly associated
with higher histological grade (P00.000), steroid receptors
negativity (P00.000), CK5/6 positivity (P00.026), TOP-
OIIα overexpression (P00.005) and higher proliferation
rate (P00.001) (Table 1). The proportion of p53 positive
tumors was also significantly higher (P00.001) in HER2+
and basal-like breast cancer immunophenotypes than in
luminal A and B subtypes (Table 1). The same relations
were observed when p53LI was analyzed as continues var-
iable (data not shown). No other significant interactions
between p53 status and further clinical and histopathological
parameters were observed (Table 1).
Univariate Influence of Markers on DFS
To examine the relation between the MVD and DFS the
patients were divided into two groups: those with lower and
those with higher MVD tumors, initially on the basis of
mean (182.9 vessel/mm2) and median (173.4 vessel/mm2)
values. Using these cutoff points, there were no significant
differences in DFS observed between patients with lower
and higher MVD tumors (Table 2). Additionally, we tested
67th, 75th, 80th and 90th percentiles as cutoff points. The
value of 214.8 microvessels/mm2 i.e. 75th percentile had the
most potent statistical value as a cutoff point (Table 2). All
women (n049) with higher MVD (>214.8 microvessels/
mm2) survived 5 years without any evidence of cancer
disease, whereas patients with lower MVD were character-
ised by significantly (P00.016) worse DFS (79.7 %)
(Fig. 2). When Kaplan-Meier curves were analyzed with
consideration to patient subgroups, significant differences
in DFS were obtained for older women (P00.026, Fig. 3a),
patients with T2 (P00.021, Fig. 3b) and grade 3 tumors
(P00.036, Fig. 3c) and for women undergoing mastectomy
(P00.020, Fig. 3d). This effect was also observed only in
the group of patients with ER (P00.028, Fig. 4a) or PgR
negative (P00.046, Fig. 4b) and TOPOIIα overexpressed
tumors (P00.008, Fig. 4c).
The significant relation between p53 status and DFS was
observed. Patients with p53 negative tumors ware charac-
terized by significantly (P00.023) higher DFS (88.3 %) in
comparison to those with p53 positive cancers (78.7 %)
(Fig. 5). The impact on DFS was more evident in the group
of patients with PgR (P00.045, Fig. 6a) and HER2 positive
tumors (P00.036, Fig. 6b) with lower proliferation rate
(P00.015, Fig. 6c) and lower MVD (P00.037, Fig. 6d).
Multivariate Analysis for DFS
Previously, in this patient cohort, in the univariate analysis
we have found significantly higher DFS for patients with
tumors presenting lower histological grade and lower TOP-
OIIα [3]. Significant differences in DFS were also observed
between cancer immunophenotypes and tumor subgroups
distinguished according to TOPOIIα expression and HER2
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status as well as cancer subtypes according to TOPOIIα
expression and grade [3]. Therefore to evaluate prognostic
potential of MVD and p53 status we performed multivariate
Cox regression analysis according to two models. In
model I, including grade, TOPOIIALI, MVD and p53 sta-
tus, patients were dichotomised according to single varia-
bles (Table 3). In this model TOPOIIALI and MVD were
identified as independent prognostic parameters. In model
II, MVD and p53 status were analyzed together with: (1)
cancer immunophenotype, (2) tumor subgroups distin-
guished according to TOPOIIα expression and HER2 status
and (3) cancer subtypes according to TOPOIIα expression
and grade (Table 3). In this model MVD and cancer subtype
according to TOPOIIα expression and grade were indepen-
dent prognostic variables.
Discussion
In the present retrospective study, immunohistochemical
staining was used to determine the prognostic significance
of MVD and p53 status in a homogenous patient cohort (T1-
T2, N1-N2, M0) who received anthracyclines as adjuvant
chemotherapy. In this study we have shown, according to
our best knowledge for the first time, that all patients with
higher MVD tumors survived 5 years without any evidence
of cancer disease, whereas DFS for patients with lower
MVD cancers was 79.7 % (median follow-up 36 months).
The role of MVD as independent prognostic parameter was
also confirmed in multivariate Cox regression analysis. A
significant difference in DFS was also observed between
women with p53 negative tumors (88.3 %) and patients with
p53 positive cancers (78.7 %), however, in multivariate Cox
regression analysis p53 status did not reach statistical
significance.
In this study, higher MVD level was a favourable prog-
nostic factor for patients DFS after anthracyclines based
adjuvant chemotherapy. This finding is in concordance with
results obtained by several other authors. Ioachim et al. [16]
have analyzed MVD, using Factor VIII as endothelial
marker, in the group of 82 patients with T1-T3, N0-N+,
M0 breast cancer. They have found, similarly to us,
Table 2 Univariate Cox propor-
tional hazard model for MVD
different cutoff points and disease
free survival of 167 breast cancer
patients treated with adjuvant
anthracycline based
chemotherapy
HR hazard ratio, CI confidence
interval, MVD microvessel
density
MVD cutoff point Response HR 95 % CI P-value
N (%)
Median value:
Higher MVD>173.4 vessel/mm2 77/85 (90.6) 1.000
Lower MVD≤173.4 vessel/mm2 65/82 (79.3) 1.047 0.344–2.653 0.402
Mean value:
Higher MVD>182.9 vessel/mm2 64/71 (90.1) 1.000
Lower MVD≤182.9 vessel/mm2 77/96 (80.2) 1.655 0.210–1.742 0.362
67th percentile:
Higher MVD>202.0 vessel/mm2 49/52 (94.2) 1.000
Lower MVD≤202.0 vessel/mm2 91/115 (79.1) 3.307 0.075–1.212 0.081
75th percentile:
Higher MVD>214.8 vessel/mm2 49/49 (100.0) 1.000
Lower MVD≤214.8 vessel/mm2 98/123 (79.7) 17.184 0.004–0.897 0.016
80th percentile:
Higher MVD>226.6 vessel/mm2 35/35 (100.0) 1.000
Lower MVD≤226.6 vessel/mm2 107/132 (81.1) 19.144 0.002–1.515 0.035
90th percentile:
Higher MVD>265.0 vessel/mm2 23/23 (100.0) 1.000
Lower MVD≤265.0 vessel/mm2 120/144 (83.3) 24.680 0.000–15.211 0.187
Fig. 2 Kaplan-Meier curve for disease free survival depending on
microvessel density level
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significant correlation between higher MVD and increased
relapse free survival (RFS) and overall survival (OS). In
turn, Protopapa et al. [17] in a small group of 26 premono-
pausal women with ductal invasive, 2–5 cm in diameter
carcinomas, treated before or after mastectomy with anthra-
cyclines, have shown longer survival in the group of
patients with higher MVD (assessed by Masson’s Trichrome
technique) tumors. Gunel et al. [18] in 42 early breast cancer
patients (T1-2, N0-2, M0), revealed that anthracycline based
adjuvant chemotherapy was particularly effective in lymph
node positive breast cancer patients with increased angio-
genesis. One of possible explanations of positive correlation
between higher MVD and better results of anthracyclines
treatment is related with the mechanisms of these drugs’
action. A principal mechanism of anthracycline cytotoxic
effects is their ability to intercalate into DNA and to inhibit
topoisomerase II activity. Along with topoisomerase inhibi-
tion, anthracyclines stimulate the formation of reactive ox-
ygen species (ROS), which at high level, can significantly
contribute to the cytotoxic activity of these drugs through
induction of cell death, apoptosis and senescence [29].
Therefore, in well vascularized tumors, with good oxygen
access, the production of ROS may be even 2-fold greater
[30] and thus cytotoxicity may be also greater. It has been
also suggested that ROS, as signalling molecules, stimulate
angiogenesis process via induction of redox sensitive gene
expression (VEGF, matrix metalloproteinases, urokinase
plasminogen activator) [31]. Taking into account all these
facts, it is a kind of positive feedback loop, in which high
level of ROS (result of anthracycline acction) stimulates
Fig. 3 Kaplan-Meier curves for disease free survival in relation of microvessel density level in respect to patient’s age a, tumor size b, histological
grade c and type of surgery d
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higher cytotoxicity and activates new vessel formation that
is responsible for even higher ROS level. Higher antharcy-
cline sensitivity in more vascularised tumors may be also
related with increased cytotoxic agents access to tumor cells.
By contrast, there are three studies, in which reverse
correlation between MVD and the patients survival after
anthracycline based adjuvant chemotherapy was found. In
the group of 215 women with T1-T3, N+, M0 breast cancer
treated with four cycles of doxorubicin–containing therapy
followed by high doses of cyclophosphamide/cisplatin/car-
mustine, Nieto et al. [8] have found significantly longer RFS
and OS for patients with lower MVD tumors. Similar rela-
tion was found in the studies of Tas et al. [9] in the group of
120 breast cancer (T1-T3, N0-3, M0) patients treated with
CAF or cyclophosphamide/methotrexate/fluorouracil
(CMF) and of Viens et al. [10] who studied 135 women
Fig. 4 Kaplan-Meier curves for disease free survival in relation of microvessel density level in respect to estrogen receptor a, progesterone receptor
b and topoisomerase IIα expression c
Fig. 5 Kaplan-Meier curve for disease free survival depending on p53 status
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with breast cancer (T0-3, N1-3, M0) after CAF. The authors
explain these results by important role of angiogenesis in
tumor growth, invasion and metastasis [7, 32].
Moreover, there are several papers [11–15], in which no
significant relation between MVD level and treatment out-
come after anthracyclines based adjuvant chemotherapy was
obtained. The discordances in results concerning the MVD
prognostic value may be a consequence of many reasons.
First of all, in many studies, great heterogeneity in adjuvant
chemotherapy schedule and tumor clinical stage was ob-
served [9, 12, 13]. Besides, some studies, in which higher
MVD level was related with worse treatment outcome,
analyzed relatively long term follow-up (9 years in the study
of Nieto et al. [8], and 5 years in Viens et al. [10]). As in our
study the median follow-up was 36 months, it could be
speculated that the prognostic significance of MVD may
change during follow-up time and higher MVD level is
related with good prognosis within 3 years after initial
treatment. Another reason of contrary results respecting
MVD prognostic potential is connected with differences in
the methodology and criteria of MVD evaluation. These
differences concern the use of different antibodies (Factor
VIII [12, 15, 16], CD-31 [8, 10, 11, 14], CD-34 [9, 13],
endoglin [11]) characterised by different specificity [33], the
method applied to count vessels (hot spot method [8, 11, 12,
14–16] or Chalkley count [13]) and “hot spot” technique
modification concerning the number of analyzed hot spots,
which can vary from 1 (first hot-spot method) [9], trough 3
[12–14, 16] to 5 [10] or more [15]. Moreover, there are
some discrepancies between authors concerning cutoff
Fig. 6 Kaplan-Meier curves for disease free survival in relation of p53 status in respect to progesterone receptor status a, HER2 status b,
proliferation rate c and microvessel density d
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points used to distingiush lower and higher MVD tumor
subgroups. We identified cutoff point at the level of 75th
percentile which is quite often found as statistically most
potent by other authors [8, 33]. In other reports median
[9–12, 14, 15], or tertiles [13, 18] were used as a cutoff
point.
In the present study, MVD did not correlate with TOPOIIα
expression, nevertheless on the basis of these two biomarkers
we were able to identify a subgroup of patients without any
evidence of early recurrence after anthracycline treatment [3].
As we have shown, higher MVD (in our study, “low risk”
patient group) was significantly related with lower N stage,
hormonal receptors positivity and cytokeratin 5/6 negativity.
Previously we have shown that lower TOPOIIα expression in
tumors (indicated also patients with good prognosis) was
significantly related with lower histologial grade, hormonal
receptor positivity, cytokeratin 5/6 negativity, p53 negativity,
lower proliferation rate and luminal A immunophenotype [3].
All these observations may suggest that these two biomarkers:
MVD and TOPOIIα expression, allow for identification of
two different subgroups of patients, both characterised by good
prognosis and hence confirm the hypothesis that different
molecular mechanisms are responsible for sensitivity or resis-
tance to chemotherapy [29].
In our study p53 negativity was significantly related to
longer DFS. This finding is in accordance with the results of
other authors [21–24]. They have reported statistically sig-
nificant association between p53 immunopositivity and lack
of response to adjuvant anthracycline based chemotherapy.
Also in experimental studies performed on cell lines [19] or
on mice with p53 lacking tumors [20] this effect was seen.
These results can be explained in part by the fact that certain
p53 gene can up-regulate the expression of multidrug resis-
tance gene (MDR1) via stimulation of gene promoter [34].
Moreover, p53 has the key role in apoptosis activation.
However, some reports [25–27] failed to show a p53 prog-
nostic potential determined by immonohistochemistry for
response to adjuvant chemotherapy with anthracyclines.
Table 3 Multivariate Cox re-
gression analysis
HR hazard ratio, CI confidence
interval, TOPOIIALI topoiso-
merase IIα labelling index,MVD




cLuminal A-ER+, PgR+, HER2-,
CK5/6-; Luminal B-ER+,




dTOPOIIALI ≤ 11.9 % and
HER2+, TOPOIIALI>11.9 %
and HER2+, TOPOIIALI>1.9 %
and HER2-
eTOPOIIALI≤11.9 % and
G3, TOPOIIALI>11.9 % and
G3, TOPOIIALI>11.9 %
and G1+G2




3 1.271 0.438–3.494 0.648
TOPOIIALIa:
≤11.9 % 1.000
>11.9 % 6.284 0.188–21.011 0.021
MVDb:
>214.8 vesels/mm2 1.000
≤214.8 vesels/mm2 13.695 0.007–0.807 0.034
p53LI:
≤10.0 % 1.000




≤214.8 vesels/mm2 18.357 0.005–0.614 0.040
p53LI:
≤10.0 % 1.000
>10.0 % 1.941 0.767–4.910 0.163
Breast cancer immunofenotype:
Luminal Ac 1.000
Otherc 1.657 0.592–4.639 0.338
Breast cancer subtypes according to TOPOII α expression and HER2 status:
TOPOIIALI≤11.9 % and HER2- 1.000
Otherd 3.849 0.571–25.896 0.169
Breast cancer subtypes according to TOPOII α expression and grade:
TOPOIIALI≤11.9 % and G1+G2 1.000
Othere 18.357 1.561–75.897 0.021
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Lack of association between p53 mutations and p53 immu-
noreactivity may explain, in part, these contradictionary
results. Lack of immunostaining is particularly frequent in
tumors with p53 nonsense mutations [35]. Mutations in p53
may have also different biological effects. Some studies
have shown that mutations in L2 and L3 domains, which
are critical regions responsible for DNA binding, were as-
sociated with poor prognosis in breast cancer and correlated
with resistance to doxorubicin [26, 35]. In turn, Bug et al.
[36] have shown that even closely related anthracyclines
induce the synthesis of different, opposing transcripts from
p53 locus. Therefore, the minor differences in treatment
schedule can influence the results concerning p53 prognostic
role.
Conclusion
In the present study we have shown, according to our best
knowledge for the first time, that all patients with higher
MVD tumors are characterized by a very good prognosis
during the first 3 years after completion of adjuvant anthracy-
cline based treatment. Additionaly, these results suggest that
MVD may have also predictive potential, because women
with low MVD tumors are possible candidates for alternative
than anthracyclines adjuvant chemotherapy. However, we
plan to verify presented results in additional analysis with
longer follow-up.
Acknowledgments This work was supported by the Polish Ministry
of Education and Science, grant number N401 173 31/3808.
Conflict of Interest The authors declare that they have no known
conflicts of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
(2005) Effects of chemotherapy and hormonal therapy for early
breast cancer on recurrence and 15-year survival: an overview of
the randomised trials. Lancet 365(9472):1687–717
2. Andre F, Pusztai L (2006) Heterogeneity of breast cancer among
patients and implications for patient selection for adjuvant chemo-
therapy. Pharm Res 23(9):1951–8
3. Biesaga B, Niemiec J, Ziobro M, Wysocka J, Kruczak A (2011)
Prognostic potential of topoisomerase IIα and HER2 in a retro-
spective analysis of early advanced breast cancer patients treated
with adjuvant anthracycline chemotherapy. Breast 20(4):338–350
4. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angio-
genesis and metastasis correlation with invasive breast carcinoma. N
Engl J Med 324:1–8
5. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P,
Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F (1994)
Tumor microvessel density, expression, tumor size, and peritumoral
lymphatic vessel invasion are relevant prognostic markers in node-
negative breast carcinoma. J Clin Oncol 12(3):454–66
6. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum
RR, Hellman S (1996) Angiogenesis as a predictor of long-term
survival for patients with node-negative breast cancer. J Natl
Cancer Inst 88(23):1764–69
7. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel
density as a prognostic factor in women with breast cancer: a
systematic review of the literature and meta-analysis. Cancer Res
64(9):2941–55
8. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz
S (2007) Prognostic analysis of tumor angiogenesis, determined by
microvessel density and expression of vascular endothelial growth
factor, in high-risk primary breast cancer patients treated with
high-dose chemotherapy. Br J Cancer 97(3):391–7
9. Tas F, Yavuz E, Aydiner A, Saip P, Disci R, Iplikci A (2000)
Angiogenesis and p53 protein expression in breast cancer: prog-
nostic roles and interrelationships. Am J Clin Oncol 23(6):546–53
10. Viens P, Jacquemier J, Bardou VJ et al (1999) Association of
angiogenesis and poor prognosis in node-positive patients receiving
anthracycline-based adjuvant chemotherapy. Breast Cancer Res Treat
54(3):205–12
11. Gluz O, Wild P, Liedtke C, Kates R et al (2011) Tumor angiogenesis
as prognostic and predictive marker for chemotherapy dose-
intensification efficacy in high-risk breast cancer patients within the
WSG AM-01 trial. Breast Cancer Res Treat 126(3):643–51
12. Kanjanapanjapol S, Wongwaisayawan S, Phuwapraisirisan S,
Wilasrusmee C (2007) Prognostic significance of microvessel den-
sity in breast cancer of Thai women. JMed Assoc Thai 90(2):282–90
13. Hansen S, Sørensen FB, Vach W, Grabau DA, Bak M, Rose C
(2004) Microvessel density compared with the Chalkley count in a
prognostic study of angiogenesis in breast cancer patients. Histo-
pathology 44(5):428–36
14. Ludovini V, Sidoni A, Pistola L et al (2003) Evaluation of the
prognostic role of vascular endothelial growth factor and micro-
vessel density in stages I and II breast cancer patients. Breast
Cancer Res Treat 81(2):159–68
15. Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ,
BudmanDR, Henderson IC, Norton L, Hayes DF (2002) Association
of angiogenesis and disease outcome in node-positive breast cancer
patients treated with adjuvant cyclophosphamide, doxorubicin, and
fluorouracil: a Cancer and Leukemia Group B correlative science
study from protocols 8541/8869. J Clin Oncol 20(3):732–42
16. Ioachim E, Charchanti A, Charalabopoulos K, Tsanou H, Briasoulis E,
Karavasilis V, Pavlidis N, Agnantis NJ (2002) The prognostic evalu-
ation of tumor angiogenesis in invasive breast carcinoma. Electronic
Journal of Pathology and Histology 8.1 021–02
17. Protopapa E, Delides GS, Révész L (1993) Vascular density and
the response of breast carcinomas to mastectomy and adjuvant
chemotherapy. Eur J Cancer 29A(10):1391–3
18. Gunel N, Akcali Z, Coskun U, Akyol G, Yamac D, Yenidünya S
(2002) Prognostic importance of tumor angiogenesis in breast carci-
noma with adjuvant chemotherapy. Pathol Res Pract 198(1):7–12
19. Fedier A, Moawad A, Haller U, Fink D (2003) p53-deficient cells
display increased sensitivity to anthracyclines after loss of the
catalytic subunit of the DNA-dependent protein kinase. Int J Oncol
23(5):1431–7
20. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE,
Fisher DE, Housman DE, Jacks T (1994) p53 status and the
efficacy of cancer therapy in vivo. Science 266(5186):807–10
Prognostic Potential of MVD and p53 Status in Breast Cancer 959
21. Malamou-Mitsi V, Gogas H, Dafni U et al (2006) Evaluation of the
prognostic and predictive value of p53 and Bcl-2 in breast cancer
patients participating in a randomized study with dose-dense se-
quential adjuvant chemotherapy. Ann Oncol 17(10):1504–11
22. Faneyte IF, Peterse JL, Van Tinteren H et al (2004) Predicting early
failure after adjuvant chemotherapy in high-risk breast cancer
patients with extensive lymph node involvement. Clin Cancer
Res 10(13):4457–63
23. Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P,
Nisticò C, Di Filippo F, Vasselli S, Vici P, Botti C (2000) Role of
P53 and BCL-2 in high-risk breast cancer patients treated with
adjuvant anthracycline-based chemotherapy. J Cancer Res Clin
Oncol 126(12):722–29
24. Thor AD, Berry DA, Budman DR et al (1998) erbB-2, p53, and
efficacy of adjuvant therapy in lymph node-positive breast cancer.
J Natl Cancer Inst 90(18):1346–60
25. Chrisanthar R, Knappskog S, Løkkevik E et al (2011) Predictive
and prognostic impact of TP53 mutations and MDM2 promoter
genotype in primary breast cancer patients treated with epirubicin
or paclitaxel. PLoS One 6(4):e19249
26. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF,
Lillehaug JR, Akslen LA, Børresen-Dale AL (2001) Influence of
TP53 gene alterations and c-erbB-2 expression on the response to
treatment with doxorubicin in locally advanced breast cancer.
Cancer Res 61(6):2505–12
27. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM
(1997) Predictive value of c-erbB-2, p53, cathepsin-D and histology
of the primary tumor in metastatic breast cancer. Br J Cancer 76
(7):917–22
28. Kaplan EL,Meier P (1958)Nonparametric estimation from incomplete
observations. J Am Statl Association 53:457–81
29. Chien AJ, Moasser MM (2008) Cellular mechanisms of resistance
to anthracyclines and taxanes in cancer: intrinsic and acquired.
Semin Oncol 35(2 Suppl 2):S1–S14
30. Khromova NV, Kopnin PB, Stepanova EV, Agapova LS, Kopnin
BP (2009) p53 hot-spot mutants increase tumor vascularization via
ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer
Lett 276(2):143–51
31. Ushio-Fukai M (2006) Redox signaling in angiogenesis: Role of
NADPH oxidase. Cardiovascular Res 71:226–35
32. Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A,
Dziki A, Kruk-Jeromin J (2011) Angiogenesis markers quantifica-
tion in breast cancer and their correlation with clinicopathological
prognostic variables. Pathol Oncol Res 17(4):809–17
33. Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ,
Winstanley J (1997) Examining the technique of angiogenesis
assessment in invasive breast cancer. Br J Cancer 76(8):1046–54
34. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M,
Finlay C, Levine AJ (1993) Gain of function mutations in p53. Nat
Genet 4(1):42–6
35. Chrisanthar R, Knappskog S, Lokkevik E et al (2008)
CHEK2 mutations affecting kinase activity together with
mutations in TP53 indicate a functional pathway associated with
resistance to epirubicin in primary breast cancer. PLoS ONE 3(8):
e3062
36. Bug M, Dobbelstein M (2011) Anthracyclines induce the accumula-
tion of mutant p53 through E2F1-dependent and -independent mech-
anisms. Oncogene 30(33):3612–24
960 B. Biesaga et al.
